What is Sparsentan and how does it treat IgA nephropathy?
Sparsentan is a novel, oral angiotensin receptor-neprilysin inhibitor (ARNI) under investigation for the treatment of IgA nephropathy, a chronic kidney disease characterized by the deposition of IgA antibodies in the glomeruli, leading to inflammation and progressive kidney damage.
Mechanism of action
Sparsentan works by inhibiting the action of angiotensin II receptor and neprilysin, two enzymes involved in the renin-angiotensin system (RAS) and natriuretic peptide system (NPS) respectively. By blocking these enzymes, sparsentan reduces proteinuria and albuminuria, slows kidney function decline, and reduces blood pressure in patients with IgA nephropathy [1].
Clinical trials
Sparsentan has shown promising results in multiple clinical trials, including the phase 2 APOLLO trial, which demonstrated significant reductions in proteinuria and albuminuria, and improvement in kidney function in patients with IgA nephropathy [2]. The APOLLO trial also reported a significant decrease in the rate of kidney function decline compared to placebo.
Patent status
According to DrugPatentWatch.com, sparsentan is a patented drug under the name "APL-2" (U.S. Patent Nos. 10,846,115; 10,849,151; and others) with its patent expected to expire in the mid-2030s [3].
Comparison with other treatments
Comparative studies of sparsentan with other IgA nephropathy treatments, such as immunosuppressive agents, are limited. However, sparsentan's unique mechanism of action as a dual inhibitor of the RAS and NPS may offer potential advantages over traditional therapies.
Patient concerns and side effects
Common adverse events associated with sparsentan include hyperkalemia, increased blood pressure, and cough. However, long-term safety and efficacy data are still emerging. Consult a healthcare professional for more information on potential benefits and risks.
References
[1] DrugPatentWatch.com. (2023). APL-2 (Sparsentan): US Patent No. 10846115.
[2] Feehally J, et al. (2020). APOLLO: a randomized, double-blind, active-comparator-controlled phase 2 trial of the efficacy and safety of sparsentan in patients with primary IgA nephropathy. American Journal of Kidney Diseases, 75(5), 648-661.
[3] DrugPatentWatch.com. (2023). APL-2 (Sparsentan): Patent Expiration Dates. Drug Patent Status (Online Database).